Literature DB >> 7807346

Pure esophageal atresia: a 50-year review.

S H Ein1, B Shandling.   

Abstract

This review encompasses 50 years (1942 through 1991) and 69 newborns (43 boys, 26 girls). Half the babies were premature (weighing less than 2.5 kg), and about one third had other anomalies. The procedures used in this series were late primary anastomosis (17), gastric tube reconstruction (16), staging esophagostomy and gastrostomy (13), gastric pull-up (13), early primary anastomosis (4), and colon replacement (3). Four neonates received no treatment. The most common repair in the 1940s and 1950s was the gastric pull-up; the gastric tube was the most popular in the 1960s and 1970s. Delayed primary anastomosis has been the operation of choice since the 1980s. Over the last decade, it has become apparent that primary repair is successful in three quarters of such infants if the wait is 3 months and/or the newborn weight has at least doubled. This repair appears to provide the best functional result, unless there is an anastomotic stricture. Before the 1970s, the survival rate was below 40%, but since the 1980s the rate has more than doubled, to 90% in our series, regardless of the type of repair used.

Entities:  

Mesh:

Year:  1994        PMID: 7807346     DOI: 10.1016/0022-3468(94)90802-8

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  11 in total

1.  The influence of congenital heart disease on survival of infants with oesophageal atresia.

Authors:  H Leonard; A M Barrett; J E Scott; C Wren
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-11       Impact factor: 5.747

Review 2.  Delayed primary anastomosis for management of long-gap esophageal atresia: a meta-analysis of complications and long-term outcome.

Authors:  Florian Friedmacher; Prem Puri
Journal:  Pediatr Surg Int       Date:  2012-09       Impact factor: 1.827

3.  Endoscopic assessment of children with esophageal atresia: Lack of relationship of esophagitis and esophageal metaplasia to symptomatology.

Authors:  Julie Castilloux; Dorothée Bouron-Dal Soglio; Christophe Faure
Journal:  Can J Gastroenterol       Date:  2010-05       Impact factor: 3.522

4.  Total anomalous pulmonary venous drainage complicated by tracheoesophageal fistula.

Authors:  Toru Okamura; Mitsugi Nagashima; Fumiaki Shikata; Takashi Higaki; Eiichi Yamamoto; Masaaki Ohta; Hidemi Takata
Journal:  Pediatr Cardiol       Date:  2011-06-09       Impact factor: 1.655

5.  Additional congenital anomalies in babies with gut atresia or stenosis: when to investigate, and which investigation.

Authors:  R M Kimble; J Harding; A Kolbe
Journal:  Pediatr Surg Int       Date:  1997       Impact factor: 1.827

6.  Impact of preoperative diagnosis of congenital heart disease on the treatment of esophageal atresia.

Authors:  J L Encinas; A L Luis; L F Avila; L Martinez; L Guereta; L Lassaletta; Juan A Tovar
Journal:  Pediatr Surg Int       Date:  2005-11-30       Impact factor: 1.827

7.  Partial gastric pull-up in the treatment of patients with long-gap esophageal atresia.

Authors:  Marc Reismann; Tina Granholm; Henrik Ehrén
Journal:  World J Pediatr       Date:  2014-11-20       Impact factor: 2.764

Review 8.  Imaging of long gap esophageal atresia and the Foker process: expected findings and complications.

Authors:  Mark C Liszewski; Sigrid Bairdain; Carlo Buonomo; Russell W Jennings; George A Taylor
Journal:  Pediatr Radiol       Date:  2013-12-24

9.  Preservation of native esophagus in infants with pure esophageal atresia has good long-term outcomes despite significant postoperative morbidity.

Authors:  Augusto Zani; Giovanni Cobellis; Justyna Wolinska; Priscilla P L Chiu; Agostino Pierro
Journal:  Pediatr Surg Int       Date:  2015-10-31       Impact factor: 1.827

10.  Long-term results of delayed primary anastomosis for pure oesophageal atresia: a 27-year follow up.

Authors:  Thambipillai Sri Paran; Diane Decaluwe; Martin Corbally; Prem Puri
Journal:  Pediatr Surg Int       Date:  2007-05-22       Impact factor: 2.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.